Case report: Successful treatment of severe cytomegalovirus retinitis with foscarnet and intraocular injection of ganciclovir in a myelosuppressed unrelated bone marrow transplant patient

Bone Marrow Transplantation

Volumn 20, Issue 9, 1997, Pages 801-803

  Okamoto, T ^a   Okada, M ^a   Mori, A ^a   Saheki, K ^a   Takatsuka, H ^a   Wada, H ^a   Tamura, A ^a   Fujimori, Y ^a   Takemoto, Y ^a   Kanamaru, A ^b   Kakishita, E ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytomegalovirus retinitis; Foscarnet; Ganciclovir; Unrelated bone marrow transplantation

Indexed keywords

CYCLOSPORIN; FOSCARNET; GANCICLOVIR; METHOTREXATE; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY; ANTIVIRUS AGENT;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CASE REPORT; FEMALE; GRAFT REJECTION; HLA MATCHING; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINITIS; WHOLE BODY RADIATION; AQUEOUS HUMOR; DISEASE TRANSMISSION; INTRALESIONAL DRUG ADMINISTRATION;

ADULT; ANTIVIRAL AGENTS; AQUEOUS HUMOR; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS RETINITIS; FEMALE; FOSCARNET; GANCICLOVIR; HUMANS; INJECTIONS, INTRALESIONAL; LEUKEMIA, LYMPHOCYTIC, ACUTE;

EID: 0030613860     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700967     Document Type: Article

References (11)

1. Jabs DA. Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir. Infec Agent Dis 1995; 4:132-142.
2. Ganly PS, Arthur C, Goldman JM, Schulenburg WE. Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. Postgrad Med J 1988; 64: 389-391.
3. Gondo H, Minematsu T, Harada M et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol 1994; 86: 130-137.
4. Chao NJ, Schmidt GM, Niland JC et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. New Engl J Med 1993; 329: 1225-1230.
5. Bacigalupo A, Tedone E, Van Lint MT et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994; 13: 783-788.
6. Verdonck LF, de Gast GC, van Heugten HG et al. Cytomegalovirus infection causes delayed platelet recovery after bone marrow transplantation. Blood 1991; 78: 844-848.
7. Simmons P, Kaushansky K, Torok-Storb B. Mechanisms of cytomegalovirus-mediated myelosuppression: perturbation of stromal cell function versus direct infection of myeloid cells. Proc Natl Acad Sci USA 1990; 87: 1386-1390.
8. Movassagh M, Gozlan J, Senechal B et al. Direct infection of CD34+ progenitor cells by human cytomegalovirus: evidence for inhibition of hematopoiesis and viral replication. Blood 1996; 88: 1277-1283.
9. Carrigan DR, Knox KK. Human herpesvirus 6 (HHV-6) isolation from bone marrow: HHV-6-associated bone marrow suppression in bone marrow transplant patients. Blood 1994; 84: 3307-3310.
10. Knox KK, Carrigan DR. In vitro suppression of bone marrow progenitor cell differentiation by human herpesvirus 6 infection. J Infect Dis 1992; 165: 925-929.
11. Arevalo JF, Gonzalez C, Capparelli EV et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995; 172: 951-956.